Key Inclusion Criteria:

- Must weigh ≥40 kilograms

- Must have at least 2 COVID-19 signs/symptoms of mild or higher severity, or at least
1 sign/symptom of moderate or higher severity, within the 72 hours prior to
randomization, and the symptoms must still be present in the 24 hours prior to
randomization

- Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by
a nucleic acid (for example, qRT-PCR) or antigen test from any respiratory tract
specimen (for example, oropharyngeal, NP or nasal swab, or saliva), or any other
SARS-CoV-2 test approved according to local regulations, collected ≤72 hours (3
days) prior to randomization

- Oxygen saturation (SpO2) of ≥92% on room air adjusted for altitude and obtained at
rest by study staff within the 24 hours prior to randomization. For a potential
participant who regularly receives chronic supplementary oxygen for an underlying
lung condition, SpO2 measured while on standard home oxygen supplementation level
must be ≥92%.

- Capable and willing to complete an electronic participant diary

- Contraceptive use by female participants should be consistent with local regulations
regarding the use of contraceptive methods for those participating in clinical
studies. Note: The investigational medication may lead to an increase or decrease of
sex hormone levels; therefore, hormonal contraception must not be used alone and
must be combined with a barrier method.

- A woman of childbearing potential must have a negative urine pregnancy test within
the 24 hours before the first dose of investigational intervention

- Must be randomized ≤72 hours from onset of COVID-19 symptoms (defined as the time
point when at least 1 of the COVID-19 symptoms occurs)

- Agrees to not participate in another clinical trial for the treatment of COVID-19 or
SARS-CoV-2 during the study period unless meeting hospitalization criteria or
reaching Day 28, whichever is earliest

Key Exclusion Criteria:

- High risk of progression to severe COVID-19, as defined in the protocol

- Documented respiratory infection (for example, influenza, respiratory syncytial
virus) other than COVID-19 within the 14 days prior to the screening visit

- Known current renal impairment defined as estimated glomerular filtration rate <60
milliliters/minute/1.73 meters squared or requiring dialysis

- Known history of cirrhosis or liver decompensation (including ascites, variceal
bleeding, or hepatic encephalopathy)

- Known history of any of the following abnormalities in the following clinical
laboratory tests (within the 6 months prior to the screening visit):

- Total bilirubin ≥2 × upper limit of normal (ULN) (except for Gilbert's
syndrome)

- Aspartate aminotransferase or alanine aminotransferase ≥2 × ULN

- A QT interval corrected using Fridericia's formula at the screening visit:

- For males: >450 milliseconds (msec)

- For females: >470 msec

- History of hospitalization for the current SARS-CoV-2 infection or anticipated need
for hospitalization within 24 hours after randomization

- History of cancer except for basal cell or squamous epithelial carcinomas of the
skin that have been resected with no evidence of metastatic disease for 3 years

- Women with a history of osteoporosis

- Received or expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of
randomization or during the study through day 28

- Received or expected to receive any other COVID-19-specific treatment, including
outpatient remdesivir, Paxlovid, molnupiravir, monoclonal antibodies, ensitrelvir,
and convalescent plasma for the current COVID-19 infection

- Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior
to the screening visit

Note: Other protocol-defined inclusion/exclusion criteria may apply.